Entering text into the input field will update the search result below

INmune Bio GAAP EPS of -$1.88 misses by $1.30, revenue of $0.18M

Mar. 03, 2022 4:03 PM ETINmune Bio, Inc. (INMB)By: Urvi Shah, SA News Editor
  • INmune Bio press release (NASDAQ:INMB): Q4 GAAP EPS of -$1.88 misses by $1.30.
  • Revenue of $0.18M (+63.6% Y/Y).

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About INMB

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
INmune Bio, Inc.
XOMA Corporation
Altimmune, Inc.
Stoke Therapeutics, Inc.
Astria Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.